{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:24:04Z","timestamp":1790011444418,"version":"4.0.1"},"reference-count":44,"publisher":"BMJ","issue":"4","funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1035889"],"award-info":[{"award-number":["GNT1035889"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1040938"],"award-info":[{"award-number":["GNT1040938"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2016,3,23]]},"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To determine chronic opioid use pre-THA (total hip arthroplasty) and post-THA, and risk factors for persistent or new chronic opioid use post-THA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Retrospective cohort study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>Australian Government Department of Veterans' Affairs health claims database.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Participants<\/jats:title>\n                  <jats:p>9525 patients who had an elective unilateral THA between 1\/01\/2001 and 12\/31\/2012.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Primary outcome measure<\/jats:title>\n                  <jats:p>Chronic opioid use. Defined as 90\u2005days of continuous opioid use or 120\u2005days of non-continuous use.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Pre-THA, 6.2% (n=593) of patients were chronic users, while 5.2% (n=492) were post-THA. Among the 492 postoperative chronic users, 302 (61%) were chronic users pre-THA and post-THA and 190 (39%) became new chronic users after surgery. Risk factors for persistent chronic use were younger age (OR=0.96, 95% CI 0.93 to 0.99\/1-year increment), back pain (OR=1.99, 95% CI 1.20 to 3.23), diabetes (OR=3.52, 95% CI 1.05 to 11.8), hypnotics use (OR=2.52, 95% CI 1.48 to 4.30) and higher pre-THA opioid exposure (compared with opioid use for 94\u2013157\u2005days, 157\u2013224\u2005days (OR=3.75, 95% CI 2.28 to 6.18), 225+ days (OR=5.18, 95% CI 2.92 to 9.19). Risk factors for new chronic opioid use post-THA were being a woman (OR=1.40, 95% CI 1.00 to 1.96), back pain (OR=3.90, 95% CI 2.85 to 5.33), depression (OR=1.70, 95% CI 1.20 to 2.41), gastric acid disease (OR=1.62, 95% CI 1.16 to 2.25), migraine (OR=5.11, 95% CI 1.08 to 24.18), liver disease (OR=4.33, 95% CI 1.08 to 17.35), weight loss (OR=2.60, 95% CI 1.06 to 6.39), dementia (OR=2.19, 95% CI 1.04 to 4.61), hyperlipidaemia (OR=1.38, 95% CI 1.00 to 1.91), hypnotics (OR=1.56, 95% CI 1.13 to 2.16) and antineuropathic pain medication use (OR=3.11, 95% CI 2.05 to 4.72).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Patients undergoing THA are exposed to opioids for long periods of time, putting them at high risk of harm related to opioid use. We identified groups at risk of chronic opioid use, including younger patients and women, as well as modifiable risk factors of chronic opioid use, including level of opioid exposure presurgery and hypnotic use. These indicators of chronic opioid use can be used by clinicians to target patient groups for suitable pain management interventions.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2015-010664","type":"journal-article","created":{"date-parts":[[2016,4,29]],"date-time":"2016-04-29T21:54:31Z","timestamp":1461966871000},"page":"e010664","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":172,"title":["Risk factors for persistent and new chronic opioid use in patients undergoing total hip arthroplasty: a retrospective cohort study"],"prefix":"10.1136","volume":"6","author":[{"given":"Maria C S","family":"Inacio","sequence":"first","affiliation":[{"name":"Medicine and Device Surveillance Centre of Research Excellence, Sansom Institute, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Hansen","sequence":"additional","affiliation":[{"name":"Medicine and Devices Surveillance Centre of Research Excellence, School of Pharmacy and Medical Sciences, University of South Australia, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole L","family":"Pratt","sequence":"additional","affiliation":[{"name":"Medicine and Device Surveillance Centre of Research Excellence, Sansom Institute, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E","family":"Graves","sequence":"additional","affiliation":[{"name":"Australian Orthopaedic Association National Total Joint Replacement Registry, University of Adelaide, Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth E","family":"Roughead","sequence":"additional","affiliation":[{"name":"Medicine and Device Surveillance Centre of Research Excellence, Sansom Institute, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,4,29]]},"reference":[{"key":"2025101812441163000_6.4.e010664.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2007.12.013"},{"key":"2025101812441163000_6.4.e010664.2","unstructured":"Healthcare Cost and Utilization Project (HCUP). Nationwide inpatient sample (NIS). Statistical Brief 186. Secondary Healthcare Cost and Utilization Project (HCUP). Nationwide inpatient sample (NIS).Statistical Brief 186. 2014. http:\/\/www.hcup-us.ahrq.gov\/reports\/statbriefs\/sb186-Operating-Room-Procedures-United-States-2012.pdf"},{"key":"2025101812441163000_6.4.e010664.3","unstructured":"Australian Institute of Health and Welfare (AIHW). Admitted patient care 2013\u201314: Australian hospital statistics. Secondary Australian Institute of Health and Welfare (AIHW). Admitted patient care 2013\u201314: Australian hospital statistics. 2014. http:\/\/www.aihw.gov.au\/publication-detail\/?id=60129550483"},{"key":"2025101812441163000_6.4.e010664.4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2011-000435"},{"key":"2025101812441163000_6.4.e010664.5","doi-asserted-by":"crossref","first-page":"586","DOI":"10.3109\/17453674.2015.1044389","article-title":"Diabetes is associated with persistent pain after hip and knee replacement","volume":"86","author":"Rajam\u00e4ki","year":"2015","journal-title":"Acta Orthop"},{"key":"2025101812441163000_6.4.e010664.6","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-11-90"},{"key":"2025101812441163000_6.4.e010664.7","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.semarthrit.2015.05.004","article-title":"Use of prescription analgesic medication and pain catastrophizing after total joint replacement surgery","volume":"45","author":"Valdes","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"2025101812441163000_6.4.e010664.8","doi-asserted-by":"publisher","DOI":"10.3109\/15360288.2014.941132"},{"key":"2025101812441163000_6.4.e010664.9","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000000183"},{"key":"2025101812441163000_6.4.e010664.10","first-page":"1","article-title":"Prescription opioid analgesic use among adults: United States, 1999-2012","volume":"189","author":"Frenk","year":"2015","journal-title":"NCHS Data Brief"},{"key":"2025101812441163000_6.4.e010664.11","doi-asserted-by":"publisher","DOI":"10.5694\/mja10.11450"},{"key":"2025101812441163000_6.4.e010664.12","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/pds.3776","article-title":"Trends in opioid prescribing and co-prescribing of sedative hypnotics for acute and chronic musculoskeletal pain: 2001-2010","volume":"24","author":"Larochelle","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025101812441163000_6.4.e010664.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2015.02.020"},{"key":"2025101812441163000_6.4.e010664.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14966-5"},{"key":"2025101812441163000_6.4.e010664.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmn.2007.02.004"},{"issue":"(Suppl)","key":"2025101812441163000_6.4.e010664.16","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.36076\/ppj.2008\/11\/S105","article-title":"Opioid complications and side effects","volume":"11","author":"Benyamin","year":"2008","journal-title":"Pain Physician"},{"key":"2025101812441163000_6.4.e010664.17","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-8-221"},{"key":"2025101812441163000_6.4.e010664.18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.478"},{"key":"2025101812441163000_6.4.e010664.19","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-007-0322-1"},{"key":"2025101812441163000_6.4.e010664.20","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.K.01406"},{"key":"2025101812441163000_6.4.e010664.21","unstructured":"WHO. Collaborating centre for drug statistics methodology, guidelines for ATC classification and DDD assignment. 2014. Oslo, Norway, 2013. http:\/\/www.whocc.no\/filearchive\/publications\/1_2013guidelines.pdf"},{"key":"2025101812441163000_6.4.e010664.22","unstructured":"Health AGDo . Australian Goverment Department of Health. Pharmaceutical Benefits Services. Secondary Australian Goverment Department of Health. Pharmaceutical Benefits Services. 2014. http:\/\/www.pbs.gov.au\/browse\/medicine-listing"},{"key":"2025101812441163000_6.4.e010664.23","unstructured":"International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM). Secondary International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM) July 2013. 2013. https:\/\/www.accd.net.au\/Icd10.aspx"},{"key":"2025101812441163000_6.4.e010664.24","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0b013e318169d03b"},{"key":"2025101812441163000_6.4.e010664.25","unstructured":"Australian and New Zealand College of Anaesthetist FoPM. Opioid Conversion to oral Morphine Equivalent Daily Dose (oMEDD). Secondary Opioid Conversion to oral Morphine Equivalent Daily Dose (oMEDD). 2014. http:\/\/www.fpm.anzca.edu.au\/resources\/professional-documents\/OPIOID20DOSE20EQUIVALENCE.pdf"},{"key":"2025101812441163000_6.4.e010664.26","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000182534.19832.83"},{"key":"2025101812441163000_6.4.e010664.27","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-200301000-00011"},{"key":"2025101812441163000_6.4.e010664.28","first-page":"92","article-title":"Neuropathic pain\u2014a management update","volume":"42","author":"Votrubec","year":"2013","journal-title":"Aust Fam Physician"},{"key":"2025101812441163000_6.4.e010664.29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2050.2011.01287.x"},{"key":"2025101812441163000_6.4.e010664.30","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/j.1365-2036.2008.03821.x","article-title":"Nonsteroidal anti-inflammatory drug use as a risk factor for gastro-oesophageal reflux disease: an observational study","volume":"28","author":"Ruszniewski","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"2025101812441163000_6.4.e010664.31","doi-asserted-by":"publisher","DOI":"10.1007\/s00264-012-1623-5"},{"key":"2025101812441163000_6.4.e010664.32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-6576.2006.00976.x"},{"key":"2025101812441163000_6.4.e010664.33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g1251"},{"key":"2025101812441163000_6.4.e010664.34","doi-asserted-by":"publisher","DOI":"10.1177\/2151458511432758"},{"key":"2025101812441163000_6.4.e010664.35","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g6380"},{"issue":"Suppl","key":"2025101812441163000_6.4.e010664.36","doi-asserted-by":"crossref","first-page":"ES67","DOI":"10.36076\/ppj.2012\/15\/ES67","article-title":"Prescription opioid abuse in chronic pain: a review of opioid abuse predictors and strategies to curb opioid abuse","volume":"15","author":"Sehgal","year":"2012","journal-title":"Pain Physician"},{"key":"2025101812441163000_6.4.e010664.37","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.joca.2011.11.011","article-title":"The assessment of persistent pain after joint replacement","volume":"20","author":"Wylde","year":"2012","journal-title":"Osteoarthritis Cartilage"},{"key":"2025101812441163000_6.4.e010664.38","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.6.754"},{"key":"2025101812441163000_6.4.e010664.39","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1007\/s10620-013-2638-5","article-title":"Pain and opioid use in chronic liver disease","volume":"58","author":"Rogal","year":"2013","journal-title":"Dig Dis Sci"},{"key":"2025101812441163000_6.4.e010664.40","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.jalz.2014.06.013","article-title":"Frequent use of opioids in patients with dementia and nursing home residents: a study of the entire elderly population of Denmark","volume":"11","author":"Jensen-Dahm","year":"2015","journal-title":"Alzheimers Dement"},{"key":"2025101812441163000_6.4.e010664.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.01.007"},{"key":"2025101812441163000_6.4.e010664.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2013.01.012"},{"key":"2025101812441163000_6.4.e010664.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2007.02.014"},{"key":"2025101812441163000_6.4.e010664.44","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aen103"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2015-010664","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T19:44:18Z","timestamp":1760816658000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2015-010664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":44,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,4,29]]},"published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.1136\/bmjopen-2015-010664"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2015-010664","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}